Repros Therapeutics Inc. (RPRX.W)
0.83USD
9 Feb 2010
$-0.02 (-2.35%)
$0.85
$0.83
$0.83
$0.83
200
4,276,028
$10.60
$0.64
RPRX.W
About
Overall
| Beta: | -0.00 |
| Market Cap (Mil.): | $20.94 |
| Shares Outstanding (Mil.): | 25.54 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| RPRX.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | -17.20 | -- | -- |
| ROI: | -- | 1.25 | 2.30 |
| ROE: | -- | 2.09 | 2.82 |
UPDATE 3-Repros gets FDA advice on testosterone drug, shrs soar
* FDA asks to propose a label to define patient population
UPDATE 1-Repros posts wider-than-expected Q3 loss
Nov 9 (Reuters) - Cash-strapped Repros Therapeutics Inc reported a wider-than-expected quarterly loss, sending its shares down about 25 percent in pre-market trade.
UPDATE 1-Repros amends agreement over Proellex license
NEW YORK, Oct 28 (Reuters) - Repros Therapeutics Inc signed an amendment with the National Institutes of Health (NIH) to its license for Proellex, the company's experimental drug for uterine fibroids on hold for safety reasons.
UPDATE 1-Repros, Targacept to offer shares at discount
Oct 8 (Reuters) - Shares of Repros Therapeutics Inc and Targacept Inc fell sharply, after the companies said they plan to raise money by selling shares at a discount.
UPDATE 1-Repros' testosterone drug shows promise, shares soar
(Adds analyst comment, details; updates share movement)
Repros' testosterone drug successful in small study, shares soar
Oct 7 (Reuters) - Repros Therapeutics Inc said its experimental drug Androxal restored normal sperm count while increasing testosterone levels in an exploratory study, sending its shares up nearly three-fold.
Repros shares down, FDA asks for more data
NEW YORK (Reuters) - Shares of Repros Therapeutics fell 19 percent to 88 cents in premarket trading on Tuesday, after the company said the Food and Drug Administration asked for additional data on the company's lead drug Proellex to resolve the clinical hold placed on it.
UPDATE 1-Repros says FDA asks for more data on lead drug
* Says new development requirements beyond its abilities
HEADLINE STOCKS-Some U.S. stocks on the move on Aug 17
(Updates to afternoon trading, adds Atlas Pipeline and Align/Danaher)
UPDATE 2-Repros Therapeutics runs out of cash, may go bankrupt
* Says doesn't have enough cash to fund ongoing operations
Competitors
| Price | Change | |
|---|---|---|
| Schering-Plough Corporation (SGP.N) | -- | -- |
| Solvay S.A. (SOLB.BR) | €69.65 | +0.03 |
| Auxilium Pharmaceuticals, Inc. (AUXL.OQ) | $30.97 | +0.14 |
| Watson Pharmaceuticals, Inc. (WPI.N) | $38.10 | +0.41 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
